Margaret L Guthrie1, Preetpal S Sidhu1, Emily K Hill2, Timothy C Horan2, Premchendar Nandhikonda1, Kelly A Teske1, Nina Y Yuan1, Marina Sidorko1, Revathi Rodali1, James M Cook1, Lanlan Han1, Nicholas R Silvaggi1, Daniel D Bikle3, Richard G Moore2, Rakesh K Singh2, Leggy A Arnold4. 1. Department of Chemistry and Biochemistry, University of Wisconsin, Milwaukee, WI, U.S.A. Milwaukee Institute of Drug Discovery, University of Wisconsin, Milwaukee, WI, U.S.A. 2. Molecular Therapeutics Laboratory, Program in Women's Oncology, Women and Infants' Hospital of Rhode Island, Alpert Medical School, Brown University, Providence, RI, U.S.A. 3. Endocrine Research Unit, Department of Medicine, Veterans Affairs Medical Center, San Francisco, CA, U.S.A. 4. Department of Chemistry and Biochemistry, University of Wisconsin, Milwaukee, WI, U.S.A. Milwaukee Institute of Drug Discovery, University of Wisconsin, Milwaukee, WI, U.S.A. arnold2@uwm.edu.
Abstract
AIM: To investigate the in vivo effects of 3-indolylmethanamines 31B and PS121912 in treating ovarian cancer and leukemia, respectively. MATERIALS AND METHODS: Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) and western blotting were applied to demonstrate the induction of apoptosis. Xenografted mice were investigated to show the antitumor effects of 3-indolylmethanamines. (13)C-Nuclear magnetic resource (NMR) and western blotting were used to demonstrate inhibition of glucose metabolism. RESULTS: 31B inhibited ovarian cancer cell proliferation and activated caspase-3, cleaved poly (ADP-ribose) polymerase 1 (PARP1), and phosphorylated mitogen-activated protein kinases (MAPK), JUN N-terminal kinase/stress-activated protein kinase (JNK/SAPK) and p38. 31B reduced ovarian cancer xenograft tumor growth and PS121912 inhibited the growth of HL-60-derived xenografts without any sign of toxicity. Compound 31B inhibited de novo glycolysis and lipogenesis mediated by the reduction of fatty acid synthase and lactate dehydrogenase-A expression. CONCLUSION: 3-Indolylmethanamines represent a new class of antitumor agents. We have shown for the first time the in vivo anticancer effects of 3-indolylmethanamines 31B and PS121912. Copyright
AIM: To investigate the in vivo effects of 3-indolylmethanamines 31B and PS121912 in treating ovarian cancer and leukemia, respectively. MATERIALS AND METHODS: Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) and western blotting were applied to demonstrate the induction of apoptosis. Xenografted mice were investigated to show the antitumor effects of 3-indolylmethanamines. (13)C-Nuclear magnetic resource (NMR) and western blotting were used to demonstrate inhibition of glucose metabolism. RESULTS: 31B inhibited ovarian cancer cell proliferation and activated caspase-3, cleaved poly (ADP-ribose) polymerase 1 (PARP1), and phosphorylated mitogen-activated protein kinases (MAPK), JUN N-terminal kinase/stress-activated protein kinase (JNK/SAPK) and p38. 31B reduced ovarian cancer xenograft tumor growth and PS121912 inhibited the growth of HL-60-derived xenografts without any sign of toxicity. Compound 31B inhibited de novo glycolysis and lipogenesis mediated by the reduction of fatty acid synthase and lactate dehydrogenase-A expression. CONCLUSION:3-Indolylmethanamines represent a new class of antitumor agents. We have shown for the first time the in vivo anticancer effects of 3-indolylmethanamines 31B and PS121912. Copyright
Authors: Kenneth Ewan; Bozena Pajak; Mark Stubbs; Helen Todd; Olivier Barbeau; Camilo Quevedo; Hannah Botfield; Rodrigo Young; Ruth Ruddle; Lee Samuel; Alysia Battersby; Florence Raynaud; Nicholas Allen; Stephen Wilson; Branko Latinkic; Paul Workman; Edward McDonald; Julian Blagg; Wynne Aherne; Trevor Dale Journal: Cancer Res Date: 2010-07-07 Impact factor: 12.701
Authors: Michèle Rouleau; Anand Patel; Michael J Hendzel; Scott H Kaufmann; Guy G Poirier Journal: Nat Rev Cancer Date: 2010-03-04 Impact factor: 60.716
Authors: Lukas Peiffer; Simon Jonas Poll-Wolbeck; Hanna Flamme; Iris Gehrke; Michael Hallek; Karl-Anton Kreuzer Journal: J Cancer Res Clin Oncol Date: 2014-05-04 Impact factor: 4.553
Authors: Preetpal S Sidhu; Nicholas Nassif; Megan M McCallum; Kelly Teske; Belaynesh Feleke; Nina Y Yuan; Premchendar Nandhikonda; James M Cook; Rakesh K Singh; Daniel D Bikle; Leggy A Arnold Journal: ACS Med Chem Lett Date: 2014-02-13 Impact factor: 4.345
Authors: Premchendar Nandhikonda; Wen Z Lynt; Megan M McCallum; Tahniyath Ara; Athena M Baranowski; Nina Y Yuan; Dana Pearson; Daniel D Bikle; R Kiplin Guy; Leggy A Arnold Journal: J Med Chem Date: 2012-05-16 Impact factor: 7.446